BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc., the leader in prescription digital therapeutics (PDTs), today announced that Christopher D.T. Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer, will present at Oppenheimer’s 29th Annual Healthcare Conference in New York on Tuesday, March 19 at 9:45 a.m. Eastern Time.
Pear Therapeutics is a privately held, prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious disease.
About Pear Therapeutics
Pear Therapeutics is the
leader in prescription digital therapeutics. We aim to redefine medicine
by discovering, developing, and delivering clinically validated
software-based therapeutics to provide better outcomes for patients,
smarter engagement and tracking tools for clinicians, and cost-effective
solutions for payers. Pear has a pipeline of products and product
candidates across therapeutic areas, including severe psychiatric and
neurological conditions. Our lead product, reSET®, treats Substance Use
Disorder and was the first prescription digital therapeutic to receive
marketing authorization from the FDA to treat disease. Pear’s second
product, reSET-O™, for the treatment of Opioid Use Disorder, received
marketing authorization from the FDA in December 2018. For more
information, visit us at www.peartherapeutics.com.
